CoChat

Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial

Open access
Davies, Melanie J., Bain, Stephen C., Atkin, Stephen L., Rossing, Peter, Scott, David, Shamkhalova, Minara S., Bosch-Traberg, Heidrun, Syrén, Annika, Umpierrez, Guillermo E. · 2016 · Diabetes Care

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Renal impairment in type 2 diabetes limits available glucose-lowering treatment options. This trial was conducted to establish the efficacy and safety of liraglutide as an add-on to existing glucose-lowering medications in patients with inadequately controlled type 2 diabetes and moderate renal impairment. RESEARCH DESIGN AND METHODS: In this 26-week, double-blind trial, 279 patients with HbA1c 7–10%, BMI 20–45 kg/m2, and moderate renal impairment (estimated glomerular filtration rate [eGFR] 30–59 mL/min/1.73 m2; MDRD) were randomized (1:1) to once-daily liraglutide 1.8 mg (n = 140) or placebo (n = 139). RESULTS: The estimated treatment difference in HbA1c from baseline to week 26 was −0.66% (−7.25 mmol/mol) (95% CI −0.90 to −0.43 [−9.82 to −4.69]), P < 0.0001). Fasting plasma glucose decreased more with liraglutide (−1.22 mmol/L [−22.0 mg/dL]) than with placebo (−0.57 mmol/L [−10.3 mg/dL], P = 0.036). There was a greater reduction in body weight with liraglutide (−2.41 kg) than with placebo (−1.09 kg, P = 0.0052). No changes in renal function were observed (eGFR relative ratio to baseline: −1% liraglutide, +1% placebo; estimated treatment ratio [ETR] 0.98, P = 0.36). The most common adverse events were gastrointestinal (GI) adverse effects (liraglutide, 35.7%; placebo, 17.5%). No difference in hypoglycemic episodes was observed between treatment groups (event rate/100 patient-years of exposure: liraglutide, 30.47; placebo, 40.08; P = 0.54). The estimated ratio to baseline for lipase was 1.33 for liraglutide and 0.97 for placebo (ETR 1.37, P < 0.0001). CONCLUSIONS: Liraglutide did not affect renal function and demonstrated better glycemic control, with no increase in hypoglycemia risk but with higher withdrawals due to GI adverse events than placebo in patients with type 2 diabetes and moderate renal impairment.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc14-2883

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Research works printed but not linked: 1

  1. Scott, 2014, Efficacy and safety of liraglutide versus placebo by eGFR subgroup in subjects with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized trial (Abstract), J Am Soc Nephrol, 25, 75A

Cited by

Items 101–200 of 234

Metadata

Authors
Davies, M. J., Bain, S. C., Atkin, S. L., Rossing, P., Scott, D., Shamkhalova, M. S., Bosch-Traberg, H., Syrén, A., & Umpierrez, G. E.
Affiliations
  • University of Leicester (GB)
  • Swansea University (GB)
  • Weill Cornell Medical College in Qatar (QA)
  • Steno Diabetes Center, Gentofte, Denmark
  • Clinical Research Development Associates, Rosedale, NY
  • Department of Diabetic Nephropathy, Endocrinology Research Centre, Moscow, Russia
  • Novo Nordisk A/S, Søborg, Denmark
  • Novo Nordisk (Denmark) (DK)
  • Emory University (US)
Corresponding author
Davies, Melanie J.
Venue
Diabetes Care
Published
2015-12-17
Volume
39
Issue
2
Pages
222-230
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2236659707
Cited by
235
References
35
Citations by year
2026: 19 · 2025: 20 · 2024: 17 · 2023: 28 · 2022: 18 · 2021: 19 · 2020: 24 · 2019: 22 · 2018: 28 · 2017: 24 · 2016: 16
FWCI
19.71
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by)
  • Leicester Research Archive (University of Leicester) (submittedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
liraglutide, type 2 diabetes, renal dysfunction, glycemic control, HbA1c, fasting blood glucose, weight loss, renal function, lipase, hypoglycemia, gastrointestinal adverse effects, GLP-1 receptor agonists, GIP receptor agonist, GIP/GLP-1 receptor agonist
MeSH terms
Liraglutide, Adolescent, Adult, Aged, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Gastrointestinal Tract, Renal Insufficiency

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.